Andere Sprachen Cessatech A/S

Aktien

CESSA

DK0061411964

CESSA

Schlusskurs NORDIC GROWTH MARKET Andere Börsenplätze 00:00:00 26.04.2024			% 5 Tage	% 1. Jan.
6,62 ^DKK	+1,85 %		+5,08 %	-8,82 %

29.02.	Cessatech A/S meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
2023	Cessatech A/S meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

A short business update	18.04.
Minutes from the Annual General Meeting in Cessatech A/S	27.03.
Annual General Meeting - 27 March 2024	11.03.
Cessatech A/S publishes Annual Report for the fiscal year 2023	29.02.
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2	30.01.
LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024	23.01.
CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2	22.01.
CESSATECH ANNOUNCES THE START OF THE EXERCISE PERIOD FOR WARRANTS OF SERIES TO2	12.01.
CESSATECH ANNOUNCES TO2 WARRANT EXERCISE PRICE AND START OF EXERCISE PERIOD	11.01.
Q&A session related topline data Study 0205	04.01.
Cessatech: Cessatech announces positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001	22.12.
Third Quarter Report Q3-2023	16.11.
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16.11.
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children	25.10.23
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	25.10.23
Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001	21.09.23
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	21.09.23
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	12.09.23
Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children	12.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cessatech A/S

Aktien

CESSA

DK0061411964

CESSA

Andere Sprachen

Filter